The role of AP-1 in glucocorticoid resistance in leukaemia.
Glucocorticoids are used in the treatment of acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) but many patients develop glucocorticoid resistance on relapse. The ligand-activated glucocorticoid receptor inhibits activity of the AP-1 transcription factor and the purpose of this study was to test the hypothesis that up-regulation or overexpression of AP1-binding activity may be an important mechanism of glucocorticoid resistance in ALL and CLL. In vitro sensitivity of patient blasts to prednisolone was measured using th
Bailey
S
S
Department of Child Health, University of Newcastle upon Tyne, UK.
Hall
A G
AG
Pearson
A D
AD
Redfern
C P
CP
D000328:Adult; D001483:Base Sequence; D015152:Blotting, Northern; D015153:Blotting, Western; D002675:Child, Preschool; D017931:DNA Primers; D019008:Drug Resistance, Neoplasm; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000378:metabolism / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000378:metabolism / Q000473:pathology*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism; D018808:Transcription Factor AP-1 / Q000502:physiology*
D017931:DNA Primers; D005938:Glucocorticoids; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D018808:Transcription Factor AP-1